Creative Biolabs provides end-to-end Clostridium butyricum engineering services that connect strict-anaerobic strain construction with functional, stability, safety, and process evidence for live biotherapeutic drug discovery. Our scientists help teams select workable tools, protect engineered performance during cultivation, and prepare characterized strains for efficient downstream preclinical study execution.
Engineering Clostridium butyricum for live biotherapeutic discovery requires more than a successful edit. Restriction barriers, low transformation efficiency, oxygen sensitivity, sporulation, plasmid loss, and pathway burden can disconnect genotype from function during construction or scale-up. Selected strains are attractive chassis because of their probiotic background, gastrointestinal passage, butyrate production, and potential for engineered metabolite or payload delivery.
Creative Biolabs connects chassis and tool selection, knockout, knock-in, or regulated expression with strict-anaerobic cultivation, functional testing, genetic stability, safety planning, and preclinical handoff. Vector and editing strategies are selected strain by strain, accounting for restriction-modification background, selectable markers, promoter activity, donor design, and plasmid curing so confirmed clones can advance as stable, testable candidates.
We provide modular or integrated services for creating and characterizing engineered C. butyricum strains, with each work package designed around the client's intended mechanism, available starting materials, and next preclinical decision.
We review host-strain genotype, native plasmids, restriction-modification systems, selectable markers, sporulation behavior, and oxygen sensitivity before recommending an editing and recovery route. Candidate shuttle vectors, integration strategies, promoters, and induction systems are assessed for compatibility with the selected chassis.
Decision value: reduces avoidable construction cycles and identifies feasibility constraints before wet-lab execution.
Our scientists design and construct target strains using a client-supplied scheme or a literature-informed strategy. The scope can include gene knockout, gene knock-in, chromosomal insertion, or expression-cassette introduction, followed by clone screening, sequence confirmation, and a documented construction history.
Decision value: delivers genotype-confirmed strains with a transparent record of design and selection logic.
Validation is configured around the engineering objective. Options include sequencing, protein expression by Western blot or PAGE, targeted metabolite analysis, growth and sporulation phenotyping, and a client-selected cell-based or biochemical assay. Controls and acceptance logic are defined before testing so the final data answer a development question rather than merely confirm activity.
Decision value: distinguishes a correct edit from a strain that performs the intended biological function.
Serial-passage or process-relevant studies can assess retention of the edit, expression cassette, and functional phenotype. Safety-oriented characterization may include identity and purity, antimicrobial susceptibility planning, absence of unintended construct elements where applicable, and risk-based assays aligned with the strain and intended research use.
Decision value: reveals whether engineered function persists under conditions that matter to manufacturing and preclinical use.
We connect strain construction to anaerobic cultivation, media selection, inoculum strategy, fermentation monitoring, harvest timing, cryopreservation, and recovery testing. Process conditions are evaluated for their effect on viability, yield, sporulation, metabolite output, and engineered-function retention.
Decision value: prevents process conditions from silently selecting against the engineered phenotype.
Strain format, dose preparation, recovery method, functional biomarkers, and study controls are mapped to the next animal-model objective. This handoff helps ensure that the material entering an efficacy, pharmacology, biodistribution, or tolerability study has an appropriate identity, viability, and potency context.
Decision value: creates continuity between engineering evidence and interpretable in vivo results.
We construct target knockout or integrated strains to client specifications or a published scheme, optimize the program to improve technical feasibility, and deliver characterized strains with the records needed to guide functional and preclinical decisions.
A stage-gated workflow keeps design, construction, phenotype, stability, and process readiness connected while allowing the scope to stop at the decision point your program needs.
Confirm the therapeutic hypothesis, target gene or pathway, host strain, available genome information, intended function, and downstream study requirements.
Select the vector or genomic strategy, guide and donor architecture, promoter and marker logic, transfer route, culture conditions, and clone-screening plan.
Execute transformation or conjugation under strict-anaerobic conditions, apply selection or counterselection, recover candidate clones, and maintain traceable culture records.
Screen junctions or deleted loci, verify the intended sequence, and add optional Western blot, PAGE, metabolite, or expression testing as appropriate.
Compare engineered and control strains, challenge function across passages or process conditions, and complete agreed risk-based characterization.
Prepare glycerol stocks, compile methods and QC results, document deviations, and align material handling and biomarkers with the next study.
Each proposal defines the construction target, test matrix, acceptance logic, and handoff format. The following baseline can be expanded for program-specific functional or process questions.
| Work Package | Core Scope | Typical Output |
|---|---|---|
| Services | Gene knockout; gene knock-in or gene insertion; optional expression or phenotype testing | Confirmed engineered clone(s) and construction summary |
| Deliverables | Engineered strains in glycerol stock with agreed storage and recovery information | Labeled strain material and certificate or data summary as scoped |
| Quality Control | Sequencing validation; optional Western blot; PAGE; or a biochemical, metabolite, or cell-based assay of interest | Genotype evidence and agreed expression or function results |
| Delivery Time | Starting from 4-6 weeks; timing depends on strain, edit complexity, recovery, and optional validation | Milestone schedule confirmed after technical review |
Construction Scheme
Overall design, intended genotype, controls, and preferred method when available.
Host Strain
A suitable culture, provenance information, and known growth or handling constraints.
Target Gene Name
Target locus, pathway role, intended knockout, insertion, or expression outcome.
Target Sequence
Target gene sequence when a reliable whole-genome sequence is unavailable.
Recent research established tetracycline-inducible CRISPR-Cas12a systems in C. butyricum and compared target-dependent deletion performance at the pyrE and spo0A loci. The image illustrates donor-template architecture and colony PCR screening for both targets, showing why editing-system selection, guide design, homologous regions, and clone-level confirmation must be planned together for a strict-anaerobic chassis. It also makes the distinction between molecular construction and evidence-based clone qualification immediately visible.
The study further connected genotype to phenotype and demonstrated that target design can materially change mutation recovery, supporting a stage-gated strategy rather than assuming that one vector works uniformly across loci. This is directly relevant when a project must compare clones, preserve the engineered phenotype, and decide whether material is ready for process or animal studies. Creative Biolabs can translate this evidence into a project-specific construction and validation plan that links the selected edit to sequence confirmation, optional expression or functional assays, stability checks, and a defined strain-banking handoff for live biotherapeutic discovery.
The chassis offers useful biological properties, but development value depends on controlling them through strain-specific engineering, verification, and anaerobic process expertise.
A potentially useful delivery and product attribute that requires deliberate control and characterization.
A native metabolic feature that can be measured, optimized, or protected during engineering.
Multiple carbon-flow and payload strategies can be explored with fit-for-purpose assays.
Selected strains offer a relevant starting point for gastrointestinal live biotherapeutic research.
Shuttle-vector, endogenous, and heterologous editing options support tailored build strategies.
One project framework connects molecular construction, analytical confirmation, anaerobic culture, functional readouts, and preclinical material requirements.
Feasibility, stability, and process risks are surfaced early, with scope and controls matched to the decision your team needs to make.
Programs can conclude with genotype-confirmed stocks or extend into expression, potency, stability, fermentation, safety, and animal-model support.
Extend strain construction with complementary design, genetic modification, integration-stability, and anaerobic fermentation capabilities selected for engineered LBP programs.
Yes. Reported approaches include electrotransformation or conjugation-mediated DNA delivery, plasmid-based transformation, and genome-editing systems for precise knockout, insertion, or multiplex modification. Method performance depends strongly on the host strain, restriction barriers, vector architecture, selection strategy, and anaerobic recovery conditions.
Published research has described C. butyricum engineered to express the NY-ESO-1 antigen, secrete SARS-CoV-2 Spike S1 antigens, produce other heterologous proteins, alter metabolic pathways, and carry integrated fluorescent reporters. These examples demonstrate technical feasibility, but they do not make different strains or constructs interchangeable. Each project still requires strain-specific feasibility review, genotype confirmation, functional validation, stability assessment, and appropriate safety planning.
We consider payload size, desired expression level and duration, selectable-marker strategy, genetic burden, copy-number variability, plasmid retention, process conditions, and downstream safety expectations. Plasmids can support rapid prototyping, while chromosomal integration may offer a more stable route for later-stage characterization. The final choice is made against the intended function and evidence plan.
We define culture and sampling conditions that track viability, growth, sporulation, construct retention, and the relevant functional readout. Comparing early and late passages or process stages helps identify burden, drift, or selection against the engineered phenotype. Media, inoculum, induction, harvest, cryopreservation, and recovery conditions can then be adjusted within the agreed scope.
Useful starting inputs are the overall construction scheme, host strain, target gene name, target sequence when a dependable whole-genome sequence is unavailable, intended function, desired controls, and downstream use. If the scheme is not yet fixed, our scientists can begin with a feasibility review and propose an engineering and validation plan.
For Research Use Only. Not intended for use in food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.
Copyright © 2026 Creative Biolabs. All Rights Reserved.
